Insight Conference

First speaker line-up of INSIGHT 2023

Professor of Psychiatry
Department of Molecular Neuroimaging, Central Institute of Mental Health Mannheim
Professor of Neuropsychopharmacology
Imperial College London, Division of Brain Sciences
Professor of Clinical Pharmacology and Internal Medicine
University Hospital, Basel
Senior Researcher, Psychologist, and Neuroscientist
University of Zürich and Yale University
Susan Hill Ward Professor of Psychedelics & Consciousness Research
Johns Hopkins University School of Medicine
Research group leader, Coach for Connective Breathwork
Ernst-Strüngmann Institute for Neuroscience
Lecturer in Philosophy & Postdoctoral Researcher
University of Western Australia & University of Adelaide
Professor in Substance Use
Public Health Institute of the Liverpool John Moores University, United Kingdom
Professor of Psychiatry and Neurosciences
Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness Research
Postdoctoral Research Fellow
Johns Hopkins Medicine, Center for Psychedelic and Consciousness Research

Looking back at INSIGHT 2021

The last edition of INSIGHT hosted over 1300 attendees in Berlin and via live stream and offered 67 talks, 8 panel discussions, 10 exploratory art experiences, and 14 pre-conference workshops. Watch the after movie and download the Conference Report to learn more.


Download Report

Get a glimpse of INSIGHT 2023

  • With the feedback and experience from 2021, we will make INSIGHT 2023 even greater, for example, by adding new elements such as multilingual conference tracks, invited symposia, and policy interaction. Participatory formats will allow us to openly discuss the pressing questions of our time, such as:
  • How can we critically learn from the past and ongoing studies?
  • Which therapist trainings have evolved, and how to assess their quality?
    What is needed to make the transition from scientific research to societal integration?

INSIGHT 2023 will also report results from the largest science-initiated psilocybin study so far: the German EPIsoDE trial.
We are building bridges between physicians and psychotherapists, researchers, and the psychedelic industry and closing the gap between practitioners and the academic world of psychedelic research.



Buy Tickets



Read what speakers and participants have said about INSIGHT



Sign up and be the first to find out about calls, announcements, opportunities to work with us, and ticket deals.